NEW YORK (GenomeWeb News) – Integromics will use a €1 million ($1.3 million) grant from the European Regional Development Fund and the Spanish government to fund a partnership with the Galician Foundation of Genomic Medicine to develop data-focused clinical genomics solutions and software.
The project, called ApliClinics LC-NGS, will focus on developing ways to better analyze and interpret the large volumes of data generated by next-generation sequencing for clinical applications.
"This will be the first time that Integromics will be working side-by-side with clinicians to bridge the gap between our NGS technology and how it translates into healthcare for patients," Eduardo Couto, Integromics' chief strategy officer, said in a statement.
"Producing the genomic data is no longer a problem, however, it is the analysis and interpretation of the data which has become the 'new frontier'. In order to characterize and interpret the data for medical usage, novel bioinformatics tools are crucially needed," Couto said.
"The interest of the group, in addition to genomic research, is the practical translation of next generation sequencing to clinical routine casework," FPGMX Director Angel Carracedo said.
"For this reason this project is essential for us. In this moment the bottleneck is not data production but to have bioinformatic tools allowing us to obtain reliable and accurate information of the variation found after DNA sequencing using NGS facilities, which is the main objective of this project."
Integromics is headquartered in Granada, Spain and has offices in Madrid and Philadelphia.